TickerTalks
Browse all tickers →
TickerTalks›$ABT
ABABT

Abbott Laboratories

$ABT·$164B·Medical - Devices·Healthcare
$98.86+10.7%YTD-28.4%1Y-32.1%
Mentions · last 7 days
2026-07-08: 74 posts2026-07-09: 104 posts2026-07-10: 187 posts2026-07-11: 86 posts2026-07-12: 131 posts2026-07-13: 243 posts2026-07-14: 134 posts965+33%
Price updated 12m ago·X counts updated 2d ago
ABABT
$ABTAbbott Laboratories
$98.86+10.74%965 posts+33%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ABT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-07-15

Falling on heavy selling — points lower unless it turns around.

Abbott is at 52-week lows, down 33% t12m and off another 3.4% today — the July 16 print has to answer why quality-med-device compounders are being punished.

Abbott Laboratories is the diversified healthcare compounder — medical devices (structural heart, diabetes CGM, electrophysiology), diagnostics (labs and rapid tests), nutrition, and established pharma. The stock is down 33% over twelve months, 29% year-to-date, and now at just the 13th percentile of the 52-week range going into the July 16 print.

Where the mechanics actually stand:

  • The underlying business is stable, not deteriorating: Q1 revenue grew 7.8% year-on-year to $11.16B on 56% gross margin and 16% operating margin, and the trailing four EPS surprises averaged just 0.2% (mostly meets, one small beat) — the model is delivering exactly what consensus expects.
  • Free cash flow is real: Q1 delivered $916M FCF and trailing FCF-to-market-cap sits at 4.7%, with FY26 EPS consensus at $5.47 growing to $6.05 in FY27 — this is a quality-compounder profile.
  • The chart is genuinely broken: shares 19% below the 200-day, down 33% over twelve months, and today's -3.4% drop into earnings adds to the pressure — the tape is treating ABT as a bagged position that funds are exiting rather than accumulating.
  • The overhang is partly governance: the DOJ closed its criminal probe into the baby-formula plant (a positive), but the $500K Trump inaugural donation and $1M in disclosed Trump-account ABT trades add a governance-flavored overhang that the market is at least partially discounting.

The July 16 earnings is the immediate test — a beat with FY26 organic-growth guide reaffirmed plus concrete diabetes-CGM traction commentary is what could stop the breakdown, while another in-line print combined with any commentary on formula-litigation reserves or CGM competitive pressure is what confirms this as a multi-quarter reset with more downside toward the 200-day trough.

What to watch: The July 16 Q2 print — FY26 organic-growth guidance, diabetes-CGM traction, and any formula-litigation reserve commentary. A beat with intact guide stops the breakdown; an in-line print with fresh reserve or competitive-pressure commentary confirms the multi-quarter reset toward the 200-day.

On the calendar: 2026-07-16 — Q2 2026 earnings

x sentiment dispersed

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment5 posts analyzed · as of 2026-07-08

The corpus mixes two distinct assets under $ABT. On Abbott the equity, the DOJ closed its criminal probe into the baby-formula plant against a backdrop of $500K donated to the Trump inaugural and up to $1M in disclosed Trump-account ABT trades — flagged as governance rather than a directional call. Separately, Arcblock $ABT is a crypto token with uniformly bullish adoption and accumulation posts. No coherent equity direction.

Read the AI verdict + X sentiment for $ABT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Sells diagnostics, cardiovascular devices, continuous glucose monitors (FreeStyle Libre), and branded generics across 160+ countries.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $ABT.

Medical - Devices · Healthcare

No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.

What this means for $ABT

Neutral — Sells diagnostics, cardiovascular devices, continuous glucose monitors (FreeStyle Libre), and branded generics across 160+ countries; this business's revenue is largely decoupled from the surgical robotics procedure growth and AI-enabled device adoption.

Industry benchmark

12-name peer basket
-11.5%YTD
+5.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
25.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
6.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
18.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
12.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
56.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 16, 2026$1.15$1.14+0.9%
Q4 2025Jan 22, 2026$1.50$1.500.0%
Q3 2025Oct 15, 2025$1.30$1.300.0%
Q2 2025Jul 17, 2025$1.26$1.260.0%
Next earningsThu, Jul 16·consensus EPS $1.28

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$11.2B+7.8%56.3%16.5%$0.62$916.0M
Q4 FY25$11.5B+4.4%57.0%19.6%$1.02$2.6B
Q3 FY25$11.4B+6.9%55.7%18.1%$0.94$2.3B
Q2 FY25$11.1B+7.4%56.4%18.4%$1.02$1.5B

Forward consensus

5-year forecast · up to 19 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$50.4B$49.7B – $50.5B$5.47$5.46 – $5.4919
FY27$54.9B$54.2B – $55.4B$6.05$5.97 – $6.1519
FY28$58.8B$58.8B – $58.9B$6.75$4.96 – $7.8218
FY29$63.1B$61.0B – $63.6B$7.56$7.23 – $7.6411
FY30$67.6B$65.3B – $68.1B$8.35$7.99 – $8.449

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.13%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-19.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.7B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.615-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMay 7John G StrattonDirector2.0K sh$174KBuyApr 27Daniel J StarksDirector10.0K sh$927KBuyApr 23Philip P BoudreauCFO2.2K sh$201KSellMar 2Louis H. MorronePresident1.1K sh$132KSellMar 2Salvadori Daniel Gesua SivePresident885 sh$102KSellMar 2Eric ShroffPresident709 sh$82KSellMar 2Elizabeth C. CushmanEVP, GC AND SECRETARY263 sh$30KSellMar 2Mary K MorelandPresident613 sh$71KSellMar 2John A. MccoyPresident585 sh$68K
+ 41 other (27 awards · 12 inkinds · 2 discretionarys) in window

See when $ABT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsApr 283
AI summary

Kevin T. Conroy, newly appointed director of Abbott Laboratories (ABT), filed an initial Form 3 as of April 24, 2026. Table I indicates beneficial ownership of Abbott common shares, but the specific count is truncated in the excerpt. Routine Section 16(a) initial ownership disclosure for a new director; administrative and non-material.

8-KOfficer or director changeApr 278-K — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

Abbott Laboratories (ABT) held its Annual Meeting on April 24, 2026 at which stockholders approved the 2026 Incentive Stock Program (replacing the 2017 Program) and elected Kevin Conroy to the Board. The 2026 Program authorizes up to 140,000,000 Abbott shares plus shares released from the 2017 Program, with full-value award shares counting as three shares against the reserve, and permits stock options, RSUs, performance awards, and other share-based grants. A new Amended and Restated By-Laws also appear to be an associated item (Item 5.03). The 2026 Program represents substantial new equity compensation capacity for Abbott and is a routine annual governance action.

3New insider — initial holdingsMar 253
8-KMaterial agreementMar 98-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
8-KMaterial agreementFeb 268-K — Item 1.01: Material agreement
424B5Prospectus supplement (offering)Feb 25424B5
S-3ASRAuto-shelf registrationFeb 23S-3ASR
8-KCharter amendmentFeb 208-K — Item 5.03: Charter amendment
+ 15 other (2 13Gs · 2 S-8s · 2 routine 8-Ks · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Reasons to Retain Abbott Stock in Your Portfolio for Nowzacks.com·1d agoNasdaq closes higher as Apple, soft PPI lift stocksproactiveinvestors.com·1d agoAbbott's Q2 Earnings on Deck: How Should You Play the Stock Now?zacks.com·2d agoAbbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?247wallst.com·3d agoUnlocking Q2 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metricszacks.com·3d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BSX$ISRG$BIO$BFLY$TMDX$ECOR$CLPT$PRCT
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport